1. Home
  2. SAFE vs LBRX Comparison

SAFE vs LBRX Comparison

Compare SAFE & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safehold Inc. New

SAFE

Safehold Inc. New

HOLD

Current Price

$16.19

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo LB Pharmaceuticals Inc

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$45.03

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFE
LBRX
Founded
2016
2015
Country
United States
United States
Employees
N/A
27
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
SAFE
LBRX
Price
$16.19
$45.03
Analyst Decision
Hold
Strong Buy
Analyst Count
10
5
Target Price
$19.00
$46.60
AVG Volume (30 Days)
274.0K
344.9K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
4.48%
N/A
EPS Growth
7.43
N/A
EPS
0.82
N/A
Revenue
$385,552,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.31
N/A
P/E Ratio
$20.01
N/A
Revenue Growth
5.43
N/A
52 Week Low
$12.76
$13.40
52 Week High
$17.45
$46.01

Technical Indicators

Market Signals
Indicator
SAFE
LBRX
Relative Strength Index (RSI) 48.86 78.18
Support Level $13.99 $27.40
Resistance Level $16.54 N/A
Average True Range (ATR) 0.49 2.95
MACD -0.07 1.08
Stochastic Oscillator 25.00 92.22

Price Performance

Historical Comparison
SAFE
LBRX

About SAFE Safehold Inc. New

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: